PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Versartis Presents Data From Up to 30 Months of Somavaratan Treatment for Pediatric Growth Hormone Deficiency at the 2016 ESPE Annual Meeting
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML
Toggle Summary Versartis to Present at the Morgan Stanley Global Healthcare Conference
MENLO PARK, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML
Toggle Summary Versartis to Host Investor Symposium Featuring Leading Experts in Growth Hormone Deficiency
MENLO PARK, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML
Toggle Summary Versartis Presents Efficacy, Safety, Metabolic and Adherence Data for Somavaratan in Oral Session at the International Congress of Endocrinology
MENLO PARK, Calif., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML
Toggle Summary Versartis Announces Completion of Enrollment in Phase 3 VELOCITY Trial of Somavaratan in Pediatric GHD
Total of 137 patients enrolled; top-line results expected in Q3 2017
View HTML
Toggle Summary Versartis Announces Completion of Enrollment in Phase 3 VELOCITY Trial of Somavaratan in Pediatric GHD
Total of 137 patients enrolled; top-line results expected in Q3 2017
View HTML
Toggle Summary Teijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan
Teijin's regulatory and commercial infrastructure ideally suited to capitalize on somavaratan, which is positioned to be the first potential long-acting form of recombinant growth hormone (rhGH) to enter the Japanese market Teijin to receive exclusive license to commercialize and further develop
View HTML
Toggle Summary Versartis to Present at the Canaccord Genuity 36th Annual Growth Conference
MENLO PARK, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML
Toggle Summary Versartis Reports Second Quarter 2016 Financial Results
Enrollment to be Complete by Mid-August in the Phase 3 VELOCITY Trial for Pediatric GHD; Data Expected Q3 2017
View HTML
Toggle Summary Versartis Reports First Quarter 2016 Financial Results
MENLO PARK, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML